128 related articles for article (PubMed ID: 26271547)
21. BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis.
Huang WF; Liu AH; Zhao HJ; Dong HM; Liu LY; Cai SX
Medicine (Baltimore); 2015 Aug; 94(33):e1263. PubMed ID: 26287412
[TBL] [Abstract][Full Text] [Related]
22. Expression of Bim, Noxa, and Puma in non-small cell lung cancer.
Sakakibara-Konishi J; Oizumi S; Kikuchi J; Kikuchi E; Mizugaki H; Kinoshita I; Dosaka-Akita H; Nishimura M
BMC Cancer; 2012 Jul; 12():286. PubMed ID: 22788963
[TBL] [Abstract][Full Text] [Related]
23. Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.
Incharoen P; Charonpongsuntorn C; Saowapa S; Sirachainan E; Dejthevaporn T; Kampreasart K; Trachu N; Muntham D; Reungwetwattana T
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3581-3589. PubMed ID: 31870097
[TBL] [Abstract][Full Text] [Related]
24. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Deng J; Shimamura T; Perera S; Carlson NE; Cai D; Shapiro GI; Wong KK; Letai A
Cancer Res; 2007 Dec; 67(24):11867-75. PubMed ID: 18089817
[TBL] [Abstract][Full Text] [Related]
25. A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC).
Azad AK; Qiu X; Boyd K; Kuang Q; Emami M; Perera N; Palepu P; Patel D; Chen Z; Cheng D; Feld R; Leighl NB; Shepherd FA; Tsao MS; Xu W; Liu G; Cuffe S
Lung Cancer; 2014 Jun; 84(3):289-94. PubMed ID: 24679952
[TBL] [Abstract][Full Text] [Related]
26. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
[TBL] [Abstract][Full Text] [Related]
27. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure.
Arrieta O; Campos-Parra AD; Zuloaga C; Avilés A; Sánchez-Reyes R; Manríquez ME; Covián-Molina E; Martínez-Barrera L; Meneses A; Cardona A; Borbolla-Escoboza JR
J Thorac Oncol; 2012 Aug; 7(8):1228-34. PubMed ID: 22659961
[TBL] [Abstract][Full Text] [Related]
28. Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation.
Isobe K; Kakimoto A; Mikami T; Kaburaki K; Kobayashi H; Yoshizawa T; Makino T; Otsuka H; Sano GO; Sugino K; Sakamoto S; Takai Y; Tochigi N; Iyoda A; Homma S
Cancer Genomics Proteomics; 2016 11-12; 13(6):475-482. PubMed ID: 27807070
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
Tiseo M; Capelletti M; De Palma G; Franciosi V; Cavazzoni A; Mozzoni P; Alfieri RR; Goldoni M; Galetti M; Bortesi B; Bozzetti C; Loprevite M; Boni L; Camisa R; Rindi G; Petronini PG; Ardizzoni A
J Thorac Oncol; 2008 Oct; 3(10):1104-11. PubMed ID: 18827605
[TBL] [Abstract][Full Text] [Related]
30. BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.
Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Corrales-Rodriguez L; Martín C; Reguart N; Archila P; Rodríguez J; Cuello M; Ortíz C; Franco S; Rolfo C; Rosell R; on behalf of the CLICaP
Oncotarget; 2016 Sep; 7(42):68933-68942. PubMed ID: 27926478
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer.
Wakabayashi Y; Masuda T; Fujitaka K; Nakashima T; Okumoto J; Shimoji K; Nishimura Y; Yamaguchi K; Sakamoto S; Horimasu Y; Miyamoto S; Iwamoto H; Ohshimo S; Hamada H; Hattori N
Cancer Sci; 2021 Jan; 112(1):369-379. PubMed ID: 33103296
[TBL] [Abstract][Full Text] [Related]
32. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
[TBL] [Abstract][Full Text] [Related]
33. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
34. High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country.
Lin CH; Shen CY; Lee JH; Huang CS; Yang CH; Kuo WH; Chang DY; Hsiung CN; Kuo KT; Chen WW; Chen IC; Wu PF; Kuo SH; Chen CJ; Lu YS; Cheng AL
PLoS One; 2015; 10(4):e0124908. PubMed ID: 25909194
[TBL] [Abstract][Full Text] [Related]
35. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
36. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
[TBL] [Abstract][Full Text] [Related]
38. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
Okamoto K; Okamoto I; Okamoto W; Tanaka K; Takezawa K; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
Cancer Res; 2010 Dec; 70(24):10402-10. PubMed ID: 21159653
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
Takeuchi S; Yano S
Respir Investig; 2014 Nov; 52(6):348-56. PubMed ID: 25453378
[TBL] [Abstract][Full Text] [Related]
40. Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia.
Soh SX; Lim JY; Huang JW; Jiang N; Yeoh AE; Ong ST
PLoS One; 2014; 9(8):e103435. PubMed ID: 25090024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
